Thus, we observe the increasing incidence of BCBM that occur mostly in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple-negative breast cancer [2,3,4,5]. This evidence concerns the gene ERBB2 and breast cancer.